new indications for glp-1 drugs Drugs: Where We Are and Where We're Going — Summit Re Oral semaglutide (Rybelsus) is the
Description
However, lawsuits say these warnings were not and continue to be inadequate to properly inform patients of potential side effects
N Engl J Med 2023;389:222132
doi: 10.1016/S1474-4422(06)70537-3
*Livongo is now part of Teladoc Health, and we are in a brand transition phase
NICE guidance (NG28) does not differentiate between agents based on anti-inflammatory properties
Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C
